Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Ryousei Sasaki, MD, PhD, Wataru Izumita, MD, Takahiro Mine, MD, Maki Asahi, MD, PhD, Yuzo Suzuki, MD, PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yasuhiko Tsukushi, MD, PhD, Yusei Aoki, MD, Shugo Kowata, MD, PhD, Ichiro Hanamura, MD, PhD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2016) 128 (22): 1607.

https://doi.org/10.1182/blood.V128.22.1607.1607

Published: 2016

Journal Articles

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Tatsuo Oyake, MD PhD, Takayuki Masuda, MD PhD, Norifumi Sugawara, MD PhD, Maki Asahi, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD PhD, Shigeki Ito, MD PhD, Yoji Ishida, MDPhD

Blood (2015) 126 (23): 4621.

https://doi.org/10.1182/blood.V126.23.4621.4621

Published: 2015

Journal Articles

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Yasunori Nakagawa, MD, PhD, Takahiro Mine, MD, Ichiro Hanamura, MD, PhD, Maki Asahi, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4954.

https://doi.org/10.1182/blood.V124.21.4954.4954

Published: 2014

Journal Articles

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Tadashi Shimoyama, MD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Tatsuo Oyake, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 1456.

https://doi.org/10.1182/blood.V124.21.1456.1456

Published: 2014

Journal Articles

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Yukiteru Fujishima, MD, Yasuhiko Tsukushi, M.D., Takahiro Mine, MD., Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 1071.

https://doi.org/10.1182/blood.V122.21.1071.1071

Published: 2013

NARROW

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Email alerts

ASH Publications

American Society of Hematology

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only